Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attracting large sums of money to fund their research and development programs. Neuron23 Inc., Neurogene Inc. and Locanabio, Inc. each recently revealed new funding totaling $100m or more to fund R&D for neurological and other diseases.
Investors and biopharma executives frequently observe that this is neurology’s heyday, including newly named Sage Therapeutics, Inc. CEO Barry...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?